Clinical trials: Pneumopathy
COVID-19, COVID-19 Immunisation
Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults
This is a phase 1, open-label, randomized clinical trial in males and non-pregnant females, 18 years of age and older, who are in good health, have no known history of COVID-19 or SARS-CoV-2 infection, and meet all other…
- Trial name
- NCT04785144
- Testing
- mRNA-1273, mRNA-1273.351
- Where
- 4 sites in United States
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Non-Small Cell Lung Cancer
Tarlox and Sotorasib in Patients With KRAS G12C Mutations
This is a Phase IB dose expansion trial with safety lead-in evaluating the safety, clinical activity/efficacy of the combination of tarloxotinib and sotorasib in patients with KRAS G12C mutation who have progressed on any small…
- Trial name
- NCT05313009
- Testing
- Sotorasib and Tarloxotinib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Medical University of South Carolina
Cystic Fibrosis
Aztreonam Aerosol to Treat Cystic Fibrosis Nasal Disease
This study is designed as a masked, two center, randomized, placebo-controlled pilot study to evaluate the safety and efficacy of nasal and oral inhalation of 75 mg aztreonam in subjects with CF and lung infection due to PA.
- Trial name
- NCT02730793
- Testing
- Oral Aztreonam, Nasal Aztreonam
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Virginia Commonwealth University
Pseudomonas Aeruginosa Infection
Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections
A major factor in the respiratory health of Cystic Fibrosis (CF) participants is the prevalence of chronic Pseudomonas aeruginosa (Pa) infections.
- Trial name
- NCT01315678
- Testing
- Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer., Tobramycin inhalation solution using a PARI LC® Plus nebulizer.
- Where
- 62 sites in Austria, Belgium and 16 more
- Volunteers
- 302 people
- Sponsor
- Insmed Incorporated
Recurrent Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer
Hypofractionated Boost Before Chemoradiation for Patients With Stage II-III Non-small Cell Lung Cancer Unsuitable for Surgery
This phase II trial studies how well giving a hypofractionated boost to the primary tumor before standard chemotherapy and radiation therapy works in treating patients with stage II or III non-small cell lung cancer that cannot…
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer
- Trial name
- NCT02262325
- Testing
- hypofractionated radiation therapy, cisplatin, etoposide
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
SARS-CoV-2, COVID-19 Vaccines
Effectiveness of BNT162b2 Formulations Using State Vaccine Registry and Insurance Claims Data
The primary purpose of this study is to learn about how well different versions of the Pfizer-BioNTech COVID-19 vaccine (called BNT162b2) work at preventing death, severe COVID-19 that requires a trip to the hospital, and overall…
- Trial name
- NCT06199934
- Testing
- Vaccination
- Where
- United States
- Volunteers
- 19,853,610 people
- Sponsor
- Pfizer
Carcinoma, Non-small Cell Lung
Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation
The purpose of this study is to establish whether patients with malignancy harboring a discoidin domain receptor 2 mutation or an inactivating B-RAF mutation will respond to dasatinib.
- Trial name
- NCT01514864
- Testing
- Dasatinib
- Where
- 24 sites in United States, Brazil and 5 more
- Volunteers
- 19 people
- Sponsor
- Bristol-Myers Squibb
Non-Small Cell Lung Cancer
Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET
MGCD265 is an orally administered receptor tyrosine kinase inhibitor that targets MET and other receptors. This study is a Phase 2 trial of MGCD265 in patients with locally advanced, unresectable or metastatic non-small cell lung…
- Trial name
- NCT02544633
- Testing
- MGCD265
- Where
- 94 sites in United States, Australia and 7 more
- Volunteers
- 68 people
- Sponsor
- Mirati Therapeutics Inc.
Coronavirus, Covid19
COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities
The primary objectives of this study are to evaluate the safety and reactogenicity profile after 1 and 2 dose administrations of investigational SARS-CoV-2 mRNA vaccine CVnCoV, and to evaluate the humoral immune responses 14 days…
- Conditions
- Coronavirus, Covid19, SARS-CoV-2, Severe Acute Respiratory Syndrome
- Trial name
- NCT04860258
- Testing
- CVnCoV Vaccine
- Where
- 4 sites in Belgium
- Volunteers
- 129 people
- Sponsor
- CureVac
Lung Cancer, Solid Tumor
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
The purpose of this study will be to evaluate the safety, tolerability, and pharmacological activity of pemigatinib in subjects with advanced malignancies.
- Conditions
- Lung Cancer, Solid Tumor, Gastric Cancer, Urothelial Cancer
- Trial name
- NCT02393248
- Testing
- Pemigatinib, Gemcitabine, Pembrolizumab
- Where
- 20 sites in United States, Denmark
- Volunteers
- 201 people
- Sponsor
- Incyte Corporation
Myositis Associated Interstitial Lund Disease (MA-ILD)
Myositis Interstitial Lung Disease Nintedanib Trial
This research study will evaluate safety and how well the study drug, nintedanib improve symptoms in participants with myositis associated interstitial lung disease (MA-ILD).
- Trial name
- MINT (NCT05799755)
- Testing
- Nintedanib, Standard of Care
- Where
- 10 sites in United States
- Volunteers
- 62 people
- Sponsor
- Rohit Aggarwal, MD
Hypoxemia, Arrhythmias
Differences in Morbidity Between a Necessity Endotracheal Suctioning Protocol Versus a Routine Endotracheal Suctioning
Morbidity frequency associated to a endotracheal suctioning is different between a necessity endotracheal suctioning protocol versus a routine endotracheal protocol.
- Conditions
- Hypoxemia, Arrhythmias, Cardiac Arrest, Ventilator Associated Pneumonia
- Trial name
- NCT01069185
- Testing
- Necessity endotracheal suctioning, Routine endotracheal suctioning
- Where
- Colombia
- Volunteers
- 92 people
- Sponsor
- Hospital Pablo Tobón Uribe
Asthma
Asthma Controller Adherence After Hospitalization
This study sets out to assess whether daily text message reminders help to enhance the consistency of use of controller medications following hospitalization for pediatric asthma patients ages 4-11 and their families.
- Trial name
- NCT02615743
- Testing
- Daily Text message reminder, Inhaled steroid canister monitor
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Children's Hospital of Philadelphia
Advanced Solid Tumors, Non-small Cell Lung Cancer
Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer
This is the first human study to use X-396 (ensartinib), a drug being developed for treatment of advanced cancers. The initial purpose of the study is to determine the largest amount of X-396 that can be safely given to humans…
- Trial name
- NCT01625234
- Testing
- Phase I: X-396 (ensartinib), Phase II: X-396 (ensartinib)
- Where
- 14 sites in United States
- Volunteers
- 131 people
- Sponsor
- Xcovery Holdings, Inc.
Carcinoma, Non-Small-Cell Lung
LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research
The present trial will investigate the efficacy and safety of nintedanib in combination with docetaxel as compared to placebo in combination with docetaxel in patients with stage IIIB/IV or recurrent NSCLC of adenocarcinoma…
- Trial name
- NCT02231164
- Testing
- docetaxel, nintedanib
- Where
- 13 sites in United States, Georgia and 1 more
- Volunteers
- 12 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Safety, Tolerability and Pharmacokinetics and Effect on Inflammation of Oral BI 1026706 in Patients With COPD
The main objective of the current trial is to investigate safety, tolerability, pharmacokinetics and effect on inflammation of oral BI 1026706 administered twice daily for 4 weeks in patients with COPD.
- Trial name
- NCT02642614
- Testing
- BI 1026706
- Where
- 10 sites in Denmark, Germany and 2 more
- Volunteers
- 120 people
- Sponsor
- Boehringer Ingelheim
Obesity, Morbid, Complications of Bariatric Procedures
The Effect of Postoperative Incentive Spirometry on Pulmonary Function and Pulmonary Complications in Bariatric Surgery
This study evaluates the omission of incentive spirometry use following bariatric surgery. Half of participants will receive an incentive spirometer while the other half will not.
- Conditions
- Obesity, Morbid, Complications of Bariatric Procedures, Pulmonary Atelectasis, Pneumonia
- Trial name
- NCT02431455
- Testing
- Incentive spirometer, No incentive spirometer
- Where
- United States
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- Lahey Clinic
Anemia, Sickle Cell
Dexamethasone to Treat Acute Chest Syndrome in People With Sickle Cell Disease
People with sickle cell disease (SCD) may develop acute chest syndrome (ACS), which is a common and serious lung condition that usually requires hospitalization.
- Trial name
- NCT00530270
- Testing
- Dexamethasone
- Where
- 6 sites in United States
- Volunteers
- 12 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Cystic Fibrosis
Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor
Study 110 is a Phase 3, multicenter study in subjects aged 6 years and older with cystic fibrosis (CF) who are homozygous for the F508del-CF transmembrane conductance regulator (CFTR) mutation and who participated in Study 109…
- Trial name
- NCT02544451
- Testing
- LUM/IVA
- Where
- 60 sites in United States, Australia and 7 more
- Volunteers
- 246 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Non-small Cell Lung Cancer
A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer
BCD-021-02 is a double-blind randomized clinical trial comparing efficacy of BCD-021 (INN: bevacizumab) and paclitaxel + carboplatin to Avastin and paclitaxel + carboplatin in inoperable or advanced non-squamous NSCLC patients…
- Trial name
- NCT01763645
- Testing
- Bevacizumab, Paclitaxel, Carboplatin
- Where
- 44 sites in Belarus, India and 2 more
- Volunteers
- 353 people
- Sponsor
- Biocad
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.